alirocumab

Ligand id: 6744

Name: alirocumab

References
1. Abifadel M, Elbitar S, El Khoury P, Ghaleb Y, Chémaly M, Moussalli ML, Rabès JP, Varret M, Boileau C. (2014)
Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs.
Curr Atheroscler Rep16 (9): 439. [PMID:25052769]
2. Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA. (2014)
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).
Am. J. Cardiol.114 (5): 711-5. [PMID:25060413]
3. Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, Merlet L, Pordy R, Baccara-Dinet MT. (2014)
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial.
Int. J. Cardiol.,  [Epub ahead of print]. [PMID:25037695]
4. Sleeman MW, Martin JH, Huang TT, MacDonald D. 
High affinity human antibodies to PCSK9.
Patent number: US8062640. Assignee: Regeneron Pharmaceuticals, Inc.. Priority date: 15/12/2008. Publication date: 22/11/2011.